In conjunction with its favourable effects on metabolic homeostasis, the overall therapeutic profile of PRAS40-treatment appears to be beneficial, compared to conventional mTORC1-inhibitors, the systemic use of which is limited by off-target effects including hyperglycemia, insulin resistance and dyslipidemia. This evidence concerns the gene AKT1S1 and Insulin resistance.